Skip to content
AnalystLens

Exelixis Annual Report, Year Ended Dec 31, 2010

Filing Date
Filed February 22, 2011
Period End
December 31, 2010
Security
EXEL
In the record · 2016–202610-K1110-Q358-K119

EXEL filed 11 annual reports (10-K), 35 quarterly reports (10-Q) and 119 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 22, 2011. Cited figures are marked; the original filing is the authoritative source.

Exelixis, Inc. (Nasdaq: EXEL) is a biotechnology company focused exclusively on developing cabozantinib (XL184), its most advanced solely-owned product candidate, for cancer.

The company reports that its current clinical program for cabozantinib focuses on metastatic castration-resistant prostate cancer and ovarian cancer, and that a global phase 3 registration trial in medullary thyroid cancer is ongoing, with top-line results expected in the first half of 2011 and a possible NDA submission in the second half of 2011. In December 2010 the company cut its workforce by 143 employees, and it reports 2010 total revenues of $185.0 milliona, a net loss attributable to Exelixis of $92.3 million, and an accumulated deficit of $1,182.1 million. Financially, the company ended 2010 with $256.4 million in cash, cash equivalents, marketable securities and long-term investments, which includes $96.9 million required to be held on deposit with Silicon Valley Bank under loan covenants.

Management states this is expected to fund operations for at least 12 months after the filing date. Total debt was $208.5 millionb at year-end, including a $124.0 million face amount secured convertible note sold to Deerfield for $80.0 million and an $80.0 million Silicon Valley Bank term loan. The GlaxoSmithKline loan balance of $35.9 million is due October 27, 2011.

The filing also discloses covenants requiring specified cash balances and working capital, and it warns that the company will need additional capital. Revenue is concentrated in collaborators: Bristol-Myers Squibb accounted for 50% of 2010 revenues and sanofi-aventis for 42%. Research and development expenses fell to $210.7 millionc in 2010 from $234.7 million in 2009, while the company's cabozantinib development is the main source of expected future spending.

Key Highlights

  1. Cabozantinib is the company's sole focus and most advanced solely-owned candidate; a phase 3 trial in medullary thyroid cancer has top-line results expected in the first half of 2011, with a possible NDA in the second half of 2011.
  2. Total revenues were $185.0 million in 2010, up from $151.8 million in 2009, driven mainly by sanofi-aventis collaboration revenue.
  3. Net loss attributable to Exelixis was $92.3 million in 2010, compared with $135.2 million in 2009; accumulated deficit stands at $1,182.1 million.
  4. Cash, cash equivalents, marketable securities and long-term investments totaled $256.4 million at December 31, 2010, including about $96.9 million on deposit with Silicon Valley Bank under covenants.
  5. Total debt was $208.5 million at year-end 2010, including the Deerfield secured convertible notes and an $80.0 million Silicon Valley Bank term loan; the GlaxoSmithKline loan of $35.9 million is due October 27, 2011.
  6. Two 2010 restructurings reduced the workforce by 399 employees in aggregate, with a further restructuring charge expected in 2011 of $25 million to $30 million under the December 2010 plan.
  7. Bristol-Myers Squibb (50%) and sanofi-aventis (42%) accounted for most 2010 revenues, highlighting customer concentration.

Frequently Asked Questions

  1. Can Exelixis fund its operations without raising more capital?

    Management anticipates that its current cash, marketable securities, long-term investments and expected collaborator funding will support operations for at least 12 months after the filing date. However, the filing states that future capital requirements will be substantial, that it may need additional funding to meet loan and covenant obligations, and that it may be unable to raise capital on favorable terms.

  2. What are the key near-term catalysts for cabozantinib?

    The company expects top-line results from its ongoing global phase 3 registration trial in medullary thyroid cancer in the first half of 2011, and it may submit an NDA in the United States in the second half of 2011. Updated interim data from the randomized discontinuation trial in prostate and ovarian cancer were presented in late 2010 and February 2011.

  3. How much debt does Exelixis carry and when does it come due?

    Total debt was $208.5 million at December 31, 2010. The GlaxoSmithKline loan ($35.9 million outstanding) is due October 27, 2011, the Deerfield notes are due June 2015, and the Silicon Valley Bank term loan is due May 31, 2017. The debt agreements contain financial covenants, including minimum cash and working capital requirements.

  4. Why did revenue rise and how dependent is the company on partners?

    Revenue rose to $185.0 million in 2010 from $151.8 million in 2009, mainly due to collaboration agreements with sanofi-aventis and a $27.4 million collaboration reimbursement from Bristol-Myers Squibb that included a $17.0 million transition payment. Bristol-Myers Squibb and sanofi-aventis accounted for 50% and 42% of 2010 revenues, respectively, so the company is heavily dependent on these partners.

  5. What restructuring actions has the company taken?

    In March 2010 the company reduced its workforce by approximately 40%, or 270 employees, and in December 2010 it reduced by 143 employees. The company recorded restructuring charges of $32.7 million in 2010 and expects additional charges of $25 million to $30 million, mostly facility-related, from the December plan, with aggregate cash expenditures of $35 million to $40 million.